GLP1R and type 2 diabetes mellitus: Exenatide was the first approved GLP-1R agonist for T2DM as a twice daily medication (Byetta: 2005) and its extended release formulation, Exenatide as Bydureon, was approved in 2012 for once weekly dosing.